Diamyd Medical (Germany) Investor Sentiment

DMN Stock  EUR 0.99  0.04  4.21%   
Roughly 55% of Diamyd Medical's stockholders are presently thinking to get in. The analysis of current outlook of investing in Diamyd Medical AB suggests that some traders are interested regarding Diamyd Medical's prospects. The current market sentiment, together with Diamyd Medical's historical and current headlines, can help investors time the market. In addition, many technical investors use Diamyd Medical AB stock news signals to limit their universe of possible portfolio assets.
Diamyd Medical stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Diamyd daily returns and investor perception about the current price of Diamyd Medical AB as well as its diversification or hedging effects on your existing portfolios.
  
few days ago at news.google.com         
Diamyd Medical reaches recruitment target in phase 3 study Diagnode-3 - Marketscreener.com
Google News at Macroaxis
over a week ago at news.google.com         
Conference on the future of type 1 diabetes screening coordinated by Diamyd - Marketscreener.com
Google News at Macroaxis
over a week ago at news.google.com         
Diamyd Medicals Chairman Anders Essen-Mller buys shares for SEK 0.45 million - Marketscreener.com
Google News at Macroaxis
over two weeks ago at news.google.com         
Diamyd Medical to present new analytical results at diabetes congress - Marketscreener.com
Google News at Macroaxis
over a month ago at news.google.com         
Major shareholder in Diamyd Medical announces subscription commitment in the rights issue - Marketsc...
Google News at Macroaxis
over a month ago at news.google.com         
Diamyd Medical receives SEK 48 million from exercise of warrants TO 3 - Marketscreener.com
Google News at Macroaxis
over three months ago at news.google.com         
Diamyd Medical Clinical results with Diamyd Medicals study drug Remygen published in scientific jour...
Google News at Macroaxis
over three months ago at news.google.com         
Penser raises motivated value for Diamyd - increased probability of market approval - Marketscreener...
Google News at Macroaxis
over three months ago at news.google.com         
Diamyd Medical receives a second Fast Track designation from the FDA - Marketscreener.com
Google News at Macroaxis
over three months ago at news.google.com         
Diamyd Medical AB Receives Second U.S. FDA Fast Track Designation for Diamyd - for the Prevention of...
Google News at Macroaxis
over six months ago at news.google.com         
8 biotech companies in Sweden you should know about - Labiotech.eu
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical publishes prospectus with regards to the rights issue - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, ...
Google News at Macroaxis
over six months ago at news.google.com         
The Board of Directors in Diamyd Medical have resolved on a rights issue of approximately SEK 114 mi...
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical AB Reports Earnings Results for the Full Year Ended August 31, 2022 - Marketscreener....
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Diamyd Medical that are available to investors today. That information is available publicly through Diamyd media outlets and privately through word of mouth or via Diamyd internal channels. However, regardless of the origin, that massive amount of Diamyd data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Diamyd Medical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Diamyd Medical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Diamyd Medical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Diamyd Medical alpha.

Diamyd Medical Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Diamyd Stock analysis

When running Diamyd Medical's price analysis, check to measure Diamyd Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diamyd Medical is operating at the current time. Most of Diamyd Medical's value examination focuses on studying past and present price action to predict the probability of Diamyd Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diamyd Medical's price. Additionally, you may evaluate how the addition of Diamyd Medical to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Commodity Directory
Find actively traded commodities issued by global exchanges
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments